Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 116

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 8
Chunk 116
---
 of the closing date of the transaction. The preliminary purchase price allocations were comprised of the components presented below, which represent the preliminary determination of the fair value of assets acquired and liabilities assumed, with the excess of the purchase price over the fair value of net identifiable assets acquired recorded to goodwill. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805. (in millions)Bolt MedicalSoniVieAll OtherGoodwill$304 $248 $300 Amortizable intangible assets142 — 142 Indefinite-lived intangible assets376 344 — Other assets acquired28 12 33 Net deferred tax assets— — 11 Liabilities assumed(22)(23)(15)Net deferred tax liabilities(46)(65)(23)$782 $516 $449 

10

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.We allocated a portion of the purchase price to the specific intangible asset categories as follows:Amount Assigned(in millions)Weighted Average Amortization Period(in years)Risk-Adjusted Discount Rates used in Purchase Price AllocationBolt Medical:Amortizable intangible assets:Technology-related$142 1215%Indefinite-lived intangible assets:In-process research and development (IPR&D)$376 N/A15%$518 SoniVie:Indefinite-lived intangible assets:IPR&D$344 N/A20%$344 All Other:Amortizable intangible assets:Technology-related$130 1318%Customer relationships12 1216%$142 Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.Contingent ConsiderationChanges in the fair value of our contingent consideration liability during the first six months of 2025 associated with current and prior period acquisitions were as follows:(in millions)Balance as of December 31, 2024$171 Amount recorded related to current year acquisitions258 Contingent consideration net